share_log

BRIEF-Medicure Updates On Percutaneous Coronary Intervention Study

BRIEF-Medicure Updates On Percutaneous Coronary Intervention Study

简介-经皮冠状动脉介入治疗研究的最新药物
reuters ·  2021/11/04 18:16

Nov 4 (Reuters) - Medicure Inc MPH.V :

路透11月4日电-Medicure Inc MPH.V:

* MEDICURE ANNOUNCES THAT THE SHORTENED AGGRASTAT® VERSUS INTEGRILIN® IN PERCUTANEOUS CORONARY INTERVENTION (SAVI-PCI) STUDY HAS MET ITS PRIMARY ENDPOINT

*Medure宣布,缩短的Aggrastat®与Integrlin®In Perkins冠状动脉介入(SAVI-PCI)研究已达到其主要终点

Source text for Eikon: ID:nCNW6qSwXa Further company coverage: MPH.V

Eikon的源文本:ID:nCNW6qSwXa进一步的公司报道:MPH.V

((Reuters.Briefs@thomsonreuters.com;))

(Reurs.Briefs@thomsonreurs.com;)

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发